anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mitochondrial dysfunction and low nicotinamide adenine dinucleotide (NAD+) levels are hallmarks of skeletal muscle ageing and sarcopenia1-3, but it is unclear whether these defects result from local changes or can be mediated by systemic or dietary cues. Here we report a functional link between circulating levels of the natural alkaloid trigonelline, which is structurally related to nicotinic acid4, NAD+ levels and muscle health in multiple species. In humans, serum trigonelline levels are reduced with sarcopenia and correlate positively with muscle strength and mitochondrial oxidative phosphorylation in skeletal muscle. Using naturally occurring and isotopically labelled trigonelline, we demonstrate that trigonelline incorporates into the NAD+ pool and increases NAD+ levels in Caenorhabditis elegans, mice and primary myotubes from healthy individuals and individuals with sarcopenia. Mechanistically, trigonelline does not activate GPR109A but is metabolized via the nicotinate phosphoribosyltransferase/Preiss-Handler pathway5,6 across models. In C. elegans, trigonelline improves mitochondrial respiration and biogenesis, reduces age-related muscle wasting and increases lifespan and mobility through an NAD+-dependent mechanism requiring sirtuin. Dietary trigonelline supplementation in male mice enhances muscle strength and prevents fatigue during ageing. Collectively, we identify nutritional supplementation of trigonelline as an NAD+-boosting strategy with therapeutic potential for age-associated muscle decline.
Chronic obstructive pulmonary disease (COPD) is a chronic, progressive and debilitating disease that affects quality of life (QOL), especially among patients living in poor environments. This study aimed to determine the influencing factors of good QOL among COPD patients living in Zhejiang, China. A cross-sectional study was conducted to collect data from participants in six tertiary hospitals in Zhejiang Province by a simple random sampling method. A validated questionnaire was used to collect general information, environmental factors, and COPD stage. The standardized St. George's Respiratory Questionnaire (SGRQ) was used to assess QOL. Logistic regression was used to determine influencing factors of good QOL among COPD patients at a significance level of α = 0.05. A total of 420 participants were recruited for analysis. The overall prevalence of patients with good QOL was 25.7%. Six variables were found to be associated with good QOL in the multivariable analysis. Patients who were employed had 2.35 times (95% CI 1.03-5.34) greater odds of having good QOL than those who were unemployed. Those whose family income was higher than 100,000 CNY had 2.49 times (95% CI 1.15-5.39) greater odds of having good QOL than those whose family income was lower than 100,000 CNY. Those who had treatment expenses less than 5,000 CNY had 4.57 (95% CI 1.57-13.30) times greater odds of having good QOL than those who had treatment expenses of 5,000 CNY or higher. Those who had mild or moderate airflow limitation were 5.27 times (95% CI 1.61-17.26) more likely to have good QOL than those who were in a severe or very severe stage of COPD. Those who had a duration of illness less than 60 months had 5.57 times (95% CI 1.40-22.12) greater odds of having good QOL than those who had a duration of illness of 120 months or more. Those who were not hospitalized within the past 3 months had 9.39 times (95% CI 1.62-54.43) greater odds of having good QOL than those who were hospitalized more than twice over the past 3 months. Socioeconomic status, disease stage and accessibility were associated with good QOL among COPD patients in Zhejiang Province, China. Increasing family income and implementing measures to improve the accessibility of medical care, including developing a proper system to decrease the cost of treatment for COPD patients, can improve patients' QOL.
The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility ( < 2 mg/mL ). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading is capability retained. The process is scalable and the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and predictable drug retention when the liposome encapsulated drug is administered in patients.
PURPOSE: Migraine is the comorbidity most frequently associated with visual snow syndrome (VSS), but the prevalence of VSS in patients with migraine (PWM) has not been studied. Our objective was to evaluate the frequency of VSS in PWM and to analyze if symptoms of VSS happened in a permanent or episodic manner (eVSS) in this population.
METHODS: We conducted a multicenter observational cross-sectional study. PWM was recruited from headache units, and a survey about the presence of visual snow symptoms was administered. The frequency and characteristics of patients that met current VSS criteria were analyzed. Demographic and clinical features of patients with VSS, eVSS, and PWM with no visual snow were compared.
RESULTS: A total of 217 PWM were included. Seventeen patients (7.8%) met the VSS criteria. VSS patients had visual aura more frequently (58.8% vs. 31%; p = 0.019) and a higher MIDAS score (96.6 vs. 47.7; p = 0.014). Fifty-eight PWM (26.7%) showed visual snow and associated features in an episodic way and were classified as eVSS. Patients with VSS showed a tendency towards a higher frequency of visual symptoms than patients with eVSS (p > 0.05). No statistically significant differences in sociodemographic characteristics and comorbid conditions were found between VSS and eVSS.
CONCLUSION: The prevalence of VSS in PWM may be higher than that described for the general population. Some PWM may present similar visual symptoms to patients with VSS but in an episodic manner. Our study reinforces the observation that the clinical spectrum of visual snow is likely to be broader than previously described.
This study aimed to assess plasma galectin-9 (Gal-9) and artemin (ARTN) concentrations as potential biomarkers to differentiate individuals with Long COVID (LC) patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) from SARS-CoV-2 recovered (R) and healthy controls (HCs). Receiver operating characteristic (ROC) curve analysis determined a cut-off value of plasma Gal-9 and ARTN to differentiate LC patients from the R group and HCs in two independent cohorts. Positive correlations were observed between elevated plasma Gal-9 levels and inflammatory markers (e.g. SAA and IP-10), as well as sCD14 and I-FABP in LC patients. Gal-9 also exhibited a positive correlation with cognitive failure scores, suggesting its potential role in cognitive impairment in LC patients with ME/CFS. This study highlights plasma Gal-9 and/or ARTN as sensitive screening biomarkers for discriminating LC patients from controls. Notably, the elevation of LPS-binding protein in LC patients, as has been observed in HIV infected individuals, suggests microbial translocation. However, despite elevated Gal-9, we found a significant decline in ARTN levels in the plasma of people living with HIV (PLWH). Our study provides a novel and important role for Gal-9/ARTN in LC pathogenesis.
Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise naturally occuring or synthetic protein, peptide, or protein fragment capable of binding to low density lipoprotein (or low density lipoprotein-like) receptors. The compositions may be administred using a pharmaceutically acceptable carrier. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes, such as cancer, mediated by undesired and uncontrolled cell proliferation particularly by inhibiting angiogenesis. Administration of the compositions of the present invention to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of such tumors.
Necroptosis and ferroptosis are two distinct forms of necrotic-like cell death in terms of their morphological features and regulatory mechanisms. These two types of cell death can coexist in disease and contribute to pathological processes. Inhibition of both necroptosis and ferroptosis has been shown to enhance therapeutic effects in treating complex necrosis-related diseases. However, targeting both necroptosis and ferroptosis by a single compound can be challenging, as these two forms of cell death involve distinct molecular pathways. In this study, we discovered that KW-2449, a previously described necroptosis inhibitor, also prevented ferroptosis both in vitro and in vivo. Mechanistically, KW-2449 inhibited ferroptosis by targeting the autophagy pathway. We further identified that KW-2449 functioned as a ULK1 (Unc-51-like kinase 1) inhibitor to block ULK1 kinase activity in autophagy. Remarkably, we found that Necrostatin-1, a classic necroptosis inhibitor that has been shown to prevent ferroptosis, also targets the autophagy pathway to suppress ferroptosis. This study provides the first understanding of how necroptosis inhibitors can prevent ferroptosis and suggests that autophagy is a targetable pathway for necroptosis inhibitors to prevent ferroptosis. Therefore, the identification and design of pharmaceutical molecules that target the autophagy pathway from necroptosis inhibitors is a promising strategy to develop dual inhibitors of necroptosis and ferroptosis in clinical application.
This group is the control group 1 (one) that will be taught using structured standard teaching content. Before teaching, participants will be applied pre tests. After teaching, they will be applied post tests.
Participants will receive a placebo capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), placebo capsule will be taken twice daily (BID) as 2 separate doses.
OBJECTIVE: Myocardial infarction, coronary heart disease is one of the serious types, come on urgent, case fatality rate is high, especially the front wall or extensive anterior wall myocardial infarction, easy to merge cardiac insufficiency, arrhythmia, even in patients with sudden death will happen, and life-threatening. The aim of this study was to investigate the effects of HOPE management mode on cardiac function, quality of life and in-hospital cardiovascular adverse events in patients with myocardial infarction.
METHODS: 118 patients with myocardial infarction hospitalized in our hospital from January 2020 to March 2022 were randomly divided into study group (n=59) and control group (n=59) and carried out a prospective study. The study group was treated with HOPE management mode, the control group was treated with conventional intervention. The LVEF, GRACE, quality of life were evaluated before intervention, 1 week after, 1 month and 3 months after intervention to evaluate the improvement of clinical symptoms, cardiac function and quality of life of patients.
RESULTS: The LVEF were increased from (42.94±2.38) % to (47.03±2.62) % in control group and from (43.51±2.45) to (52.94±3.09) in sudy group; the quality of life were increased from (42.08±7.44) points to (57.00±4.49) points in control group and (43.76±6.68) points to (69.42±8.03) points in sudy group; the GRACE score were increased from (152.10±14.52) points to (110.10±9.73) points in control group and (153.63±15.11) points to (81.71±10.21) points in sudy group, the difference were statistically significant (P < .05). All indicators in study group were better than those in control group at each time point after intervention (P < .05). Kaplan-Meier curve showed that the incidence of adverse cardiovascular events in the study group was lower than that in the control group within 3 months. Within 90 days of hospitalization, the incidence of adverse cardiovascular events were 28.81% in the control group, which was higher than 15.25% in the study group (P < .05). Kaplan-meier observation showed that the incidence of adverse cardiovascular events in control group was significantly higher than that in study group (χ2=5.586, P = .018).
CONCLUSIONS: The HOPE management model can effectively improve the cardiac function and quality of life of patients with myocardial infarction, and reduce GRACE scores and the incidence of in-hospital cardiovascular adverse events, which can as a comprehensive approach to improve clinical outcomes and enhance the quality of life for patients with myocardial infarction.
Methods, systems, and apparatus, including computer programs encoded on computer storage media, for real-time deployment of machine learning systems. One of the operations is performed by the system receiving video data from a video image capturing device. The received video data is converted into multiple video frames. These video frames are encoded into a particular color space format. The system renders a first display output depicting imagery from the multiple encoded video frames. The system performs an inference on the video frames using a machine learning network to determine the occurrence of one or more objects in the video frames. The system renders a second display output depicting graphical information corresponding to the determined one or more objects from the multiple encoded video frames. The system then generates a composite display output including the imagery of the first display output overlaid with the graphical information of the second display output.
Participants in the End-effector group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of Lexo training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
BACKGROUND: Chronic myeloid leukaemia (CML) treatment was revolutionized by tyrosine kinase inhibitors (TKIs), reducing annual mortality from 10-20% to 1-2%. This study assessed health-related quality of life (HRQoL) in patients receiving long-term TKI therapy in the Kurdistan region of Iraq.
METHODS: This observational study included 161 adult CML patients (90 males, 71 females, mean age 46.1 years) across three hospitals from January to August 2024. HRQoL was assessed using EORTC QLQ-C30 and QLQ-CML24 questionnaires, comparing outcomes between different TKIs (Imatinib, Nilotinib, and Bosutinib), gender, age groups, and comorbidity impacts.
RESULTS: Imatinib patients showed better emotional functioning than Bosutinib (80 vs. 73, p=0.027). Female patients reported more severe symptoms across multiple domains, while males demonstrated better physical, emotional, and cognitive functioning. Younger patients (<40 years) showed better HRQoL outcomes. Increasing comorbidities correlated with decreased functional scales and increased symptom burden. Significant differences were observed in pain, diarrhoea, and constipation between TKI groups.
CONCLUSION: While CML patients maintain a relatively good quality of life on TKI therapy, persistent impairments remain in certain domains. Younger age and fewer comorbidities were associated with better outcomes. Gender-specific approaches to supportive care and comprehensive health management beyond CML treatment are recommended. These findings can inform clinical decision-making and identify areas for targeted interventions to enhance the quality of life in CML patients.
PURPOSE:To obtain base powder for sustained release pharmaceutical preparations capable of releasing the medicinal substance(s) in the digestive tracts for a long time by dissolving a hydrogel and water-insoluble polymer in a good solvent therefor followed by drying. CONSTITUTION:The objective base powder can be obtained by dissolving (A) a hydrogel (e.g. of hydroxypropyl cellulose, methyl cellulose, polyvinylpyrrolidone) and (B) a water-insoluble polymer (e.g. ethyl cellulose, polymethacrylic copolymer, polyvinyl acetate) in a good solvent therefor (pref. ethyl alcohol) followed by drying. The present base powder is lower in hygroscopicity and higher in fluidity than the component A alone. Furthermore, by changing the formulation weight ratio for both the components A and B within the range (10 : 90) to (90 : 10), their releasing modes will also be changed as desired.
PROBLEM TO BE SOLVED: To maintain not only improvement of blood flow by carbonic acid gas, but a cleaning effect before activation and such conditions after activation.SOLUTION: The pack cosmetics of the invention contains a clay mineral, carbonate, and organic acid. Carbonic acid gas is mainly generated by the carbonate, the organic acid, and proper amount of water. On the other hand, the clay mineral comprising a mineral ingredient abundantly improves skin moisture retention, and contributes to detergency. Generating of the carbonic acid gas is stabilized to mildly maintain during the pack because generating of carbonic acid gas is properly regulated by viscosity of the clay mineral. The period of improving blood flow is prolonged by maintaining the proper carbonic acid gas, and further a mineral component is continued to be supplied, while detergency is exhibited in that period. Thereby, the makeup effect continues comprehensively.
This is a phase 3, open labeled, prospective cohort study to evaluate the molecular testing of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen. Approximately 100 participants will be given the molecular detection of pncA and rpsA mutations and divide into to the pyrazinamide sensitive comparator group and the pyrazinamide resistant group based on the susceptibility results. For the pyrazinamide sensitive group, the regimen contains six months of chemotherapy with pyrazinamide, amikacin, levofloxacin, plus prothionamide, followed by six months of pyrazinamide, levofloxacin, clarithromycin, plus prothionamide. For the pyrazinamide resistant group, the regimen contains six months of chemotherapy with isoniazid, amikacin, levofloxacin, plus prothionamide, followed by eighteen months of isoniazid, levofloxacin, clarithromycin, plus prothionamide.

The participants will be followed up to 24 months after the start of the treatment. The primary outcome is the sputum culture conversion and the adverse events. Safety evaluations that will be performed are the routine lab tests, blood glucose, hearing , vital signs, ECG, reporting of adverse events, physical examinations and X-rays.
BACKGROUND AND AIMS: Transarterial chemoembolization is the most common treatment used for HCC patients on liver transplant waiting list. The aims of this study are to evaluate the radio-histological correlation of the post-chemoembolization HCC response and its influence on overall survival (OS) and recurrence-free survival (RFS).
METHODS: Monocentric, retrospective study, including liver transplant patients with HCC who received chemoembolization from 2007 to 2018. The response of the hypervascular nodules was evaluated according to mRECIST, EASL.
RESULTS: A total of 70 patients with 122 hypervascular and 28 hypovascular HCCs were included. A complete radiological response concerned 34.3% patients. Concordance rates of hypervascular nodules (mRECIST, EASL and lipiodol uptake) with tumor necrosis ranged from 49% to 57%, with a specificity of 35% and a positive predictive value of 54%. Bilobar involvement was a predictive factor for incomplete radiological response. Major tumor necrosis was significantly correlated with the decrease in αFP level between the first CEL and liver transplantation. OS and RFS at 5 years were 64% and 60%, respectively, and 69% and 66% at complete radiological response.
CONCLUSION: Radiological response is significantly related to histological tumor necrosis, but with poor prediction. In case of complete radiological response, OS and RFS seem to be improved.
BACKGROUND: Oral squamous cell carcinoma (OSCC) is a serious health disease that can lead to a reduced quality of life or even death. It ranks sixth in terms of cancer expansion. It is one of India's primary causes of natural death. In OSCC such potentially malignant Disorders (PMDs) are precancerous lesions with such a high risk of progression. Tumor angiogenesis is a one of the basic biomarkers that may influence the proliferation of a precancerous lesion into the cancerous lesion. Tropomyosin receptor kinase B (TrkB), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) also play important roles in carcinogenesis by promoting angiogenesis. The construction of new vessels of blood from existing vasculature is referred as angiogenesis.
AIM OF THE STUDY: To get deep insights of immunohistochemistry expression of VEGF, BDNF, and TRKB in oral epithelial dysplasia (OED), verrucous carcinoma (VC), and OSCC.
MATERIAL AND METHODS: The study included 100 formalin-fixed paraffin-embedded tissue blocks from 20 cases of OED, 20 cases of VC, and 60 cases of OSCC [20 cases of well-differentiated oral squamous cell carcinoma (WD-OSCC), 20 cases of moderately differentiated oral squamous cell carcinoma (MD-OSCC), and 20 cases of poorly differentiated oral squamous cell carcinoma (PD-OSCC). The staining intensity and distribution of VEGF, BNDF, and TrkB were examined and statistically analyzed using analysis of variance (ANOVA), post hoc Bonferroni test, independent t-test, Pearson's Chi-square test, and Pearson's correlation coefficient test.
RESULTS: The immunoexpression of VEGF, BDNF, and TrkB was found to be elevated in the order of OEDs, VC, and OSCC. The percentage of positive was highest in PD-OSCC, followed by MD-OSCC and WD-OSCC.
CONCLUSION: Based on our findings, angiogenesis plays a significant role in tumor growth and metastasis. A substantial relationship was discovered between VEGF, BDNF, TrkB expression, and increases in vascularity throughout the transition from OEDs to VCs and OSCCs.
OBJECTIVES: Connexin43 (Cx43) is involved in the inflammation of many tissue types. Dental caries is infectious disease resulting from mineralized tissue dissolution by a specific bacterial population, causing pulp inflammation. However, Cx43's role in dental pulp remains unclear. Here, we investigated the function of Cx43 during pulp inflammation.
MATERIALS AND METHODS: We constructed a dentin injury model in Sprague-Dawley rats to investigate changes in Cx43 expression during pulp inflammation. Cx43 was inhibited in human dental pulp cells (hDPCs) that had been stimulated with lipopolysaccharide (LPS) to investigate the effect of Cx43 on inflammatory response. Promotion of TLR4-NF-κB pathway activity and special Cx43 channel inhibitors were used to clarify the function of Cx43 in hDPCs.
RESULTS: Dentin injury led to low-level inflammation in dental pulp. Following dentin injury, Cx43 expression initially decreased before gradually recovering to normal levels. Cx43 inhibition reduced LPS-induced expression of inflammatory cytokines and NF-κB pathway activity. Promotion of NF-κB pathway activity counteracted the effect of Cx43 in hDPCs. Furthermore, inhibition of Cx43 hemichannels reduced LPS-induced inflammatory cytokine expression.
CONCLUSIONS: Cx43 is involved in inflammation of dental pulp, while its inhibition reduced LPS-induced inflammation in hDPCs through NF-κB pathway via blockage of hemichannels.